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982A Meta-analysis of Patients Receiving Allogeneic
or Autologous Hematopoietic Stem Cell Transplant
in Mycosis Fungoides and Sezary Syndrome
Peggy A. Wu,1 Youn H. Kim,2 Phillip W. Lavori,3 Richard T. Hoppe,4
Keith E. Stockerl-Goldstein5The survival outlook in advanced mycosis fungoides (MF) is poor. Autologous and allogeneic stem cell trans-
plants (SCT) have been shown, in small case series and case reports, to have the potential for long-term
remission or to alter disease course. Allogeneic SCT is thought to have a curative potential secondary to
a graft-versus-lymphoma (GVL) effect. A patient-level meta-analysis was performed to compare the outcome
of allogeneic versus autologous SCT in patients with MF/Sezary syndrome (SS) using 39 cases from the lit-
erature. There were a total of 20 allogeneic and 19 autologous transplant cases. The gender, age, and stage
distribution was similar between the transplant groups. The allogeneic group received significantly more sys-
temic therapies prior to transplant (P\.0005) and had longer follow-up after transplant. Overall survival
(OS) results showed a more favorable outcome of patients who received allogeneic SCT (P 5 .027).
Event-free survival (EFS) demonstrated a more durable response in patients who received allogeneic SCT
(P 5 .002). In the allogeneic group, the majority (70%) of patients experienced persistent graft-versus-
host disease (GVHD), mostly with mild to moderate severity, and 2 of 4 deaths were related to GVHD.
Meanwhile, the majority of the deaths (8 of 10) in the autologous group were because of progressive disease.
These results support the belief that allogeneic SCToffers a better survival and disease-free outcome versus
autologous SCT in MF/SS, likely because of a GVL effect.
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Mycosis fungoides (MF) and Sezary syndrome (SS)
belong to a group of cutaneous T cell lymphomas
(CTCL) characterized by a proliferation of CD41/
CLA1/CCR41/CD72/CD262 T cells in the skin. MF
usually presents with patch and plaque lesions, but in1Division of Dermatology, Washington University, St.
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6/j.bbmt.2009.04.017advanced stages may progress to skin tumors with
greater risk for lymph node and visceral organ involve-
ment [1]. SS is the erythrodermic or leukemic form of
MF with circulating malignant T cells in the peripheral
blood and often portends a poorer prognosis [2].
Although it is the most common primary lym-
phoma of the skin, MF is rare and usually indolent.
Conventional treatments include topical nitrogen
mustard, topical high potency steroids, electron beam
radiotherapy, and phototherapy [3,4]. These treat-
ments usually produce complete or partial remission.
For mild MF disease—up to stage IIA—prognosis is
generally good. Patients with stage IA disease have
similar overall survival (OS) compared to others of
the same age, gender, and race, and median survival
is 11 years for patients with stage IB-IIA MF [5].
A subset of patients have advanced MF or SS,
which is heralded by the presence of skin tumors or
erythroderma at presentation. Other unfavorable
prognostic factors include large cell transformation
on histologic examination, and development of extrac-
utaneous disease. In these patients, prognosis is poor
with 5-year survival for stage IIB/III and stage IV
Biol Blood Marrow Transplant 15:982-990, 2009 983Allogeneic or Autologous HSCT in Mycosis Fungoides and Sezary SyndromeMF of 47% and 27%, and 15-year survival of 15% and
10%, respectively [5]. The management of advanced
MF includes chemotherapy, photopheresis, radiother-
apy, interferon-a, retinoids like bexarotene, as well as
targeted therapies such as monoclonal antibodies and
denileukin diftitox. These treatments are only
expected to be palliative with limited-duration remis-
sions [3,6].
There is hope that stem cell transplants (SCT)
have the potential to provide prolonged remissions
or possible cure of advanced MF/SS. The collective
experience in allogeneic and autologous transplant is
limited but optimistic, especially for allogeneic SCT.
A proposed gravt-versus-leukemia (GVL) effect is
thought to be responsible for higher effectiveness of
allogeneic transplants [7]. However, there have been
no controlled prospective studies to date, and the liter-
ature thus far consists of case reports, small case series,
and reviews [8].PATIENTS AND METHODS
Data Collection and Patient Selection
This retrospective meta-analysis was based on data
obtained from several sources. A PubMed search was
performed, using the phrases ‘‘mycosis fungoides’’/
‘‘Sezary syndrome’’/‘‘cutaneous T cell lymphoma’’
and ‘‘stem cell transplant,’’ to include data from previ-
ously reported cases and case series of MF/SS patients.
Patients with CD41 predominant MF or SS who
received peripheral blood or bone marrow-derived
SCTs were included in the study. Papers needed to
be written in English and published prior to March
2008 for study inclusion. In total, 9 papers on alloge-
neic SCTs in MF/SS and 7 papers on autologous
SCTs were reviewed, and all were used in the data
analysis. Staging was based on TNM and B classifica-
tion of MF/SS described by the Committee on StagingTable 1. Patient Characteristics
Total No. pts
Age (years) median
range
Gender male
female
Clinical stage (NCI 1979) at transplant IB
IIB
IIIA
IVA
IVB
Median No. prior therapies Skin-direct
Systemic*
Total follow-up time (months) median
range
Follow-up time of surviving patients (months) median
range
*Significant (P < .05) differences are marked.and Classification of MF/SS in 1979 [9]. Although
there are revised staging recommendations by the In-
ternational Society for Cutaneous Lymphomas, the
publications from which these patients were gathered
were written prior to the recent guidelines [10].
Information regarding patient age, gender, stage at
diagnosis, stage at progression, previous treatments,
type of SCT, inductive therapy, preparation/condition-
ing therapy, use of total-body irradiation (TBI) or total
skin electron beam (TSEB) therapy, remission/relapse,
graft-versus-host disease (GVHD), infection, mortality,
time of transplant, and last follow-up were obtained
from published reports. Authors were contacted by e-
mail or phone for additional information where the lit-
erature was not clear. Complete remission (CR) was de-
fined as resolution of skin, lymph node, viscera, or blood
involvement (if applicable) clinically, histologically, ra-
diographically, or molecularly, within 60 days of trans-
plant. GVHD was categorized as acute (occurring
\100 days from transplant) or chronic, and presence
at last follow-up was noted. If acute, the affected area
was noted, if possible, and if chronic, it was described
as limited or extensive. Although the terminology has
undergone debate and change, the reports described
GVHD in those terms.Statistical Analysis
Event-free survival (EFS), OS, and relapse curves
were created from the date of transplant until the
date of last follow-up or an event, and calculated by
the method of Kaplan and Meier [11]. Both log-rank
and Cox models were used for analysis. Competing
risk models were created with tests described by
Gray [12]. Two-tailed, independent samples t-tests
were used to compare means. Analyses were performed
with R version 2.2.0 and SPSS version 15.0 [13]. Dis-
ease progression, relapse, and death from any cause
defined events for EFS.Allogeneic Autologous
20 19
42 47
(21-59) (20-67)
9 10
11 9
1 1
3 9
1 (SS) 0
15 (5 SS) 5
0 4
ed 2 2
4.5 1
38 21
(1-108) (0.5-84)
45 22
(15-108) (10-84)
Table 2. Overview of the Literature with Transplant Regimens
Reference Age/Gender
Stage at
Transplant Conditioning Regimen
Myelo-
ablative? Radiation?
Type of
Transplant Disease relapse
Remission at Last
f/u Outcome @ Last f/u GVHD at Last f/u?
Molina et al., 1999,
2005 [24, 27]
22F SS/IVA CyP 60mg/kg x 2D Y Y; TBI Allo; MUD BMT N Y alive @ 108 mo Y; extensive skin
45 IIB CyP 60mg/kg x 2D Y Y; TBI Allo; sibling
matched BMT
N Y alive @ 89 mo Y; limited skin
46 SS/IVA CyP 60mg/kg x 2D Y Y; TBI and TSEB Allo; sibling
matched
PBSCT
N Y died @ 16 mo from
GVHD complications
Y; extensive skin,
oral
21F SS/IVA busulfan 16mg/kg, CyP 60mg/kg x 2D Y N Allo; sibling
matched
PBSCT
N Y alive @ 60 mo Y; limited skin
59 SS/IIIA Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; sibling
matched
PBSCT
N Y alive @ 53 mo Y; extensive skin
50 IVA Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; MUD BMT N Y alive @ 45 mo Y; limited skin
48 IVA Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; MUD BMT N Y alive @ 33 mo Y; limited skin
35 IIB Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; MUD
PBSCT
N Y died@ 1.1 mo from RSV N
Guitart et al., 2002
[14]
36M IIB CyP 120mg/kg with mesna Y Y; TBI Allo; sibling
matched BMT
N Y alive @ 54 mo N
39F SS/IVA CyP 120mg/kg with mesna, etopisode
30mg/kg
Y Y; TBI Allo; sibling
matched BMT
N Y alive @15 mo N
Burt et al., 2000
[28]
27F IVA CyP 200mg/kg Y Y; TBI Allo; sibling
matched
BMT + CD34
PBSC
Y @ 9 mo and 5
yrs
N alive s/p 1 DLI @ 60 mo Y; limited skin
Masood et al.,
2002[29]
37F IVA CyP 120mg/kg x 2 doses Y Y; TBI and TSEB Allo; sibling
matched
BMT + CD34
PBSC
N Y alive @ 24 mo Y; mild gut
Soligo et al., 2003
[30]
56M IVA Flu 30mg/m2 x 3D N Y; TBI Allo; sibling
matched
BMT + CD34
PBSC
N Y alive @ 24 mo N
47M IVA 2 cycles: Flu, 30mg/m2 x 3D + CyP
300mg/kg x 3D
N Y; TBI Allo; sibling
matched
BMT + CD34
PBSC
N Y alive @ 18 mo Y; limited skin
37M IVA 2 cycles: Flu 30mg/m2 x 3D + CyP
300mg/kg x 3D
N Y; TBI Allo; sibling
matched
BMT + CD34
PBSC
N Y died @ 2.4 mo of sepsis,
myocarditis
Y; grade II cut
aGVHD
Koeppl et al., 1994
[31]
29F IVA CyP 60mg/kg x 2D Y Y; TBI Allo; sibling
matched BMT
Y @ 70D and 4
yrs
Y alive @ 72 mo Y; limited skin
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Herbert et al.,
2004 [6],
(personal electronic
mail
communication
2008)
35M IIB Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; sibling
matched
BMT + CD3
Y @ 4mo, 13mo,
24mo
N alive s/p 4 DLIs @ 95*
mo
Y; extensive skin
49M SS, IVA Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; sibling
matched
BMT + CD3
Y @ D43 and
4mo
N died s/p 1 DLI @ 11 mo
of GVHD
complications
Y; extensive skin
48F IVA Flu, 25mg/m2 x 5D then Mel 140mg/m2 x
1D
N N Allo; sibling
matched
PBSCT
Y @ 4 and 6mo Y alive @ 17* mo Y; limited skin
Introcaso et al.,
2008 [32]
53F IVA Flu, 25mg/m2, CyP 350mg/m2 N Y; TBI Allo; sibling
matched SCT
N Y alive @ 43 mo Y; limited skin
Ferra et al., 1999
[33]
38F IVB CyP, 1500mg/m2 x 2D, carmustine
300mg/m2, etoposide 200mg/m2 x 3D
NA Y; TBI Auto: PBSCT Y @ 2mo N alive @ 22 mo NA
Sterling et al., 1995
[34]
48M IIB CyP 60mg/kg x 2, prednisone NA Y; TBI and local
rad to lower
leg
Auto: BMT Y @ 3mo N died @ 15 mo of PNA NA
Olavarria, Russell-
Jones et al., 2001
[35], [36]
47M IIB melphalan 140mg/m2 NA Y; TBI and TSEB Auto: PBSCT Y @ 2mo N alive @ 38 mo NA
52F IVA BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA N Auto: PBSCT Y @ 12mo N alive @ 26 mo NA
27M IVA etoposide 50mg/kg NA Y; TBI Auto: PBSCT Y @ 14mo N alive @ 30 mo NA
49F IVA BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA N Auto: BMT NA N died @ 0.5 mo of
septicemia
NA
38M IVA BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA Y; TSEB Auto: PBSCT Y @ 9mo N alive @ 21 mo NA
67M IIB BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA Y; TSEB Auto: PBSCT Y @ 2mo N died @ 11 mo of dz NA
42F IIB BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA N Auto: PBSCT Y @ 4mo N died @ 8 mo of dz NA
38M IIB BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA N Auto: PBSCT N Y alive @ 10 mo NA
57F IIB BCNU 450mg/m2 x 1D, etoposide
500mg/m2 x 4D, Mel 140mg/m2 x 1D
NA Y; TSEB Auto: PBSCT Y @ 1mo N died @ 3 mo of dz NA
Bigler et al., 1991
[37]
49F IVB CyP 40mg/kg x 4D, etoposide 200mg/m2
x 3D, BCNU 300mg/m2 x 1D
NA Y; TSEB Auto: BMT Y @ D64 N died @ 9.4 mo of dz NA
60M IIB NA Y; TBI and TSEB Auto: BMT Y @ D70 N died @ 55.5 mo of dz NA
49M IVA CyP 60mg/kg x 2D NA Y; TBI Auto: BMT Y @ D93 N died @ 12.6 mo of dz NA
37F IIB CyP 50mg/kg x 4D NA Y; TBI and TSEB Auto: BMT Y @ D96 N died @ 27.5 mo of dz NA
26F IIB BCNU 200mg/m2 x 3D, etoposide
800mg/m2 x 3D, cisplatin 40mg/m2 x
5D
NA Y; local rad to
mantle and
spleen, TSEB
Auto: BMT N Y alive @ 22 mo NA
41F IVB BCNU 200mg/m2 x 3D, etoposide
800mg/m2 x 3D, cisplatin 40mg/m2 x
5D
NA Y; local rad to
CNS
Auto: BMT N Y alive @ 21 mo NA
(Continued)
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986 Biol Blood Marrow Transplant 15:982-990, 2009P. A. Wu et al.RESULTS
The clinical characteristics of the allogeneic and
autologous SCT groups were similar (Table 1). There
were 39 patients total: 20 patients in the allogeneic
group, 19 in the autologous with similar gender and
age demographics (P, age 5 .236). Patients with
advanced disease, that is, stages IIB and IVA MF,
were represented in both groups, with more stage
IVA patients in the allogeneic group (15 versus 5).
Meanwhile, 6 patients in the allogeneic group and 1
patient in the autologous transplant group had SS. Al-
logeneic patients had longer follow-up times from
transplant. The median number of total therapies prior
to SCT was 6.5 in the allogeneic groups (range: 3-12)
and 3 (range: 0-8; P\ .0005) in the autologous group.
When divided into skin-directed versus systemic ther-
apies, the number of skin-directed therapies was simi-
lar between the 2 groups, whereas the allogeneic
transplant group received significantly more systemic
therapies prior to SCT (P\ .0005). Thirteen patients
in the autologous and 12 in allogeneic group received
TBI or electron beam therapy in addition to chemo-
therapy in their preparatory regimens (Table 2).
Nine patients in the allogeneic group received myeloa-
blative preparative regimens, whereas the remainder
received reduced-intensity (nonablative) protocols. In
the allogeneic group, stem cells were obtained from
the bone marrow or peripheral blood of matched sib-
lings or matched unrelated donors.
The Kaplan-Meier estimates demonstrate signifi-
cantly superior OS in the allogeneic transplant group
with P-value 5 .027 (Figure 1). OS rates at 1 and 5
years (with 95% confidence intervals [CI]) were 68%
(46%-90%) and 23% (0%-58%) in the autologous
group, and 85% (69%-100%) and 80% (62%-98%),
respectively, in the allogeneic group. EFS was also
significantly better in patients receiving an allogeneic
versus an autologous transplant (P 5 .002; Figure 2).
EFS rates at 1 and 5 years (with 95% CIs) were 20%
(1%-39%) and 0, respectively, in the autologous
group. In the allogeneic group, 1-year EFS was 65%
(44%-86%) and was 60% (37%-82%) at 5 years.
Overall, 4 patients in the allogeneic and 10 in the
autologous SCT group died in follow-up. Two of
the allogeneic deaths were secondary to infection
shortly after transplant. The remaining allogeneic
transplant recipients died from GVHD complications,
although 1 of those patients had residual MF disease at
the time of death. In contrast, of the 10 deaths in the
autologous group, 8 were of disease, 1 was of infection
in a patient with relapsed disease following transplant,
and the remaining patient died of infection shortly
after transplant.
Disease relapse accounted for the large difference
in EFS and mortality between the groups. The cumu-
lative incidence of cancer death was significantly
Figure 1. OS of patients with MF receiving an allogeneic transplant
(allo) or an autologous transplant (auto), P 5 .027.
Biol Blood Marrow Transplant 15:982-990, 2009 987Allogeneic or Autologous HSCT in Mycosis Fungoides and Sezary Syndromehigher after autologous transplant than allogeneic
transplant (Figure 3, test statistic 10.2 on 1 degree of
freedom, P 5 .0014 by the competing risk test),
whereas there was no significant difference between
the groups on noncancer deaths (test statistic 5 0.90,
P 5 .35).
The total number of events was small, rendering
multivariate analysis unreliable and of low power.
Nevertheless, we performed a number of multivariate
analyses to check for confounding variables by age,
gender, and stage, to see if the results could be ac-
counted for by imbalances in those factors. Age alone
had a nonsignificant effect on mortality (each year of
age multiplied the hazard of death by 1.04, P 5 .058
by the deviance test in the Cox model) as well as on
the event hazard (factor of 1.03 per year, P5 .17). After
adjusting for age, the treatment group effect was
slightly mitigated. Unadjusted hazards ratio (HR) for
treatment group effect on mortality was 3.5, adjusted
HR was 2.9, P-value for adjusted effect .061; for events
the corresponding HR was 3.6 unadjusted, 3.8 ad-
justed, P-value for adjusted effect .003. In the multivar-
iate competing risk regression analysis, cancer death
was increased significantly by both age (P 5 .022)
and treatment type (P5 .03), whereas noncancer death
was not associated with either age (P 5 .89) or treat-
ment type (P 5 .36). Thus, age did not appear to
confound the effects of treatment type.
The analysis of confounding by gender was com-
plicated by missing data on gender in 6 patients. How-
ever, gender by itself had no significant effect on OS or
EFS and adjustment for it did not appreciably change
either the significance or size of the treatment group
effect on either mortality or events.
As we started analyzing the possibility of con-
founding by stage, we observed a difference in the dis-
tribution of stage between the 2 treatment groups,
with a preponderance of IVA in allogeneic transplant
and of IIB in autologous transplant. Of note, in stage
IVA, 3/15 allogeneic patients died versus 2/5 in the au-
tologous group, and in stage IIB the death rates were 1/
3 for allogeneic and 6/9 for autologous. The raw death
rates were higher in the autologous group in both
stages. Other stages were so sparse they could not be
compared to the treatment groups within the other
stages. Within the subgroup of 20 IVA patients and
12 IIB patients, the mortality HR for IIB versus IVA
was 1.6, P5 .084, and the adjusted HR for autologous
treatment was 2.7 (P 5 .17), indicating some attenua-
tion of effect but not strong confounding. In summary,
the results are that stage has no impact, and the effect
of transplant type is unchanged after adjustment.
In patients who relapsed and died, the median time
to death was 9.3 months, and of the 5 allogeneic pa-
tients who relapsed only 1 died, compared to 9 of 15
relapsed autologous patients (P 5 .15). Of the 5 re-
lapses in the allogeneic group, 2 occurred in the mye-loablative group and 3 in the nonmyeloablative group.
In 3 of the 5 allogeneic recurrences (1 myeloablative, 2
nonmyeloablative), donor lymphocyte infusions were
used with some success [6,14].
The incidence of GVHD was high and nearly equal
in the myeloablative and nonmyeloablative allogeneic
transplant groups. Six of 9 (67%) patients in the myeloa-
blative group and 9 of 11 (81%) patients in the nonmye-
loablative group experienced acute GVHD (aGVHD),
ranging from grades I-III and with conjunctival, skin,
oral and gastrointestinal (GI) manifestations. Seven
and 8 patients in the myeloablative and nonmyeloabla-
tive sets, respectively, experienced chronic GVHD
(cGVHD). Ninety percent of the allogeneic SCT pa-
tients experienced aGVHD or cGVHD; however,
GVHD was only present in 70% of patients in the final
follow-up. In both transplant groups, there were ap-
proximately equal numbers of patients with limited or
extensive cGVHD. As previously mentioned, 2 of the
4 allogeneic deaths were attributed to GVHD complica-
tions. None of the patients in the autologous SCT group
experienced GVHD.DISCUSSION
Currently, there are a lack of therapies that will
achieve long-term remissions or cures in patients
with advanced stage MF or SS. Primary and salvage
treatments for advanced stages of MF include total
skin electron beam therapy, oral bexarotene, photo-
pheresis, interferons, denileukin diftitox, alemtuzu-
mab, and chemotherapeutic agents, many of which
were tried and failed in the patients included in our
meta-analysis [3,4]. Newer therapies have emerged,
such as histone deacetylase inhibitors including
Figure 2. EFS of patients with MF receiving an allogeneic transplant
(allo) or an autologous transplant (auto), P 5 .0021.
988 Biol Blood Marrow Transplant 15:982-990, 2009P. A. Wu et al.vorinostat, which was FDA-approved in 2006 for
CTCL [15]. The efficacy and optimal role of these
therapies as monotherapy, synergistic combinations,
or adjuvants are still being developed. Several promis-
ing novel or improved therapies are currently under-
going clinical trials. Of the available therapies,
hematopoietic SCT may have curative potential; how-
ever, currently no large trials exist. This report repre-
sents the first meta-analysis of allogeneic and
autologous SCTs in MF and SS, the major types of
CTCL.
Our univariate and multivariate analysis showed
a statistically significantly improvement in relapse,
OS and EFS in allogeneic versus autologous SCTs inFigure 3. Estimated cumulative incidences of cancer (CA) and non-
cancer (nonCA) mortality in allogeneic (allo) and (auto) autologous
transplant groups.MF/SS. Patients undergoing autologous SCT rely
only on the cytoreductive preparatory regimens prior
to stem cell rescue for treatment effect. In some of
our study patients, autologous SCT was unable to pro-
duce a complete remission, and autologous SCT
deaths were usually secondary to disease progression.
The decreased relapse rate and increased OS and
EFS in the allogeneic SCT may be consistent with
the theorized GVL/tumor effect. The graft-versus-tu-
mor effect was noted by Weiden et al. [16], when his
group described significantly decreased relapse rate
in leukemia patients with GVHD following allogeneic
SCT. Subsequent studies of the GVHD/GVL effect
after allogeneic SCT for leukemia and lymphoma
have substantiated a decreased relapse rate and in-
creased OS and EFS with cGVHD [17,18]. It is the
GVL effect that is thought to be responsible for pro-
ducing cancer remission following nonmyeloablative
regimens [19]. Although the association between
GVHD and decreased relapse rates is felt to be indic-
ative of GVL, data suggests there may be methods to
separate the GVL and GVHD reactions. Possible
approaches include using specific preparative regimens
[20], choice of immunosuppressive agents, or other
manipulations of specific regulatory and suppressor
cell populations [21-23]. The morbidity of allogeneic
SCT for MF/SS and other malignancies may be less-
ened in the future if these methods can be perfected
to allow the skewing of the immune system in the
GVL direction.
Allogeneic SCTs are traditionally associated with
higher risk of morbidity and mortality; however, in
this study, the number of deaths within the first year
was actually greater in the autologous group. Deaths
within the first year in patients who received an autol-
ogous transplant were largely secondary to progressive
disease (5 out of 6). In the allogeneic group, 3 of the 4
recorded deaths occurred in the first year and were sec-
ondary to infection (2) or complications of GVHD (1).
Overall there was a 20% transplant-related mortality
rate in allogeneic patients, which is comparable to
published data for other diseases.
In general, the conditions under which a candidate
may be approved for a myeloablative allogeneic SCT
are limited to patients under the age of 60. Unfortu-
nately, MF tends to occur at an average age of 60 years,
which, until recently, may have decreased the availabil-
ity of allogeneic transplant to these patients [24]. How-
ever, the use of reduced-intensity regimens (RICs)
should allow more MF patients, including patients in
their seventies, the opportunity to proceed to an allo-
geneic transplant. There was not enough data to per-
form meaningful comparisons between myeloablative
and RICs; however, the frequency of GVHD was sim-
ilar between the 2 types of preparatory regimens in this
patient population. TBI and TSEB have been associ-
ated with an increased risk of GVHD, perhaps through
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In our study, a greater percentage of patients who did
not receive TBI therapy had GVHD at last follow-up
(6 of 8 patients who did not receive TBI versus 8 of 12
patients who did). In contrast, the percentage of pa-
tients with GVHD at last follow-up was higher in pa-
tients who received electron beam therapy at some
point in their MF/SS therapy (7 or 8 patients who re-
ceived TSEB versus 7 of 12 patients who did not).
However, the statistical significance was not deter-
mined because of the small sample size.
With new advances in transplantation and the data
presented here, hematopoietic SCT for advanced MF
should be considered in patients who have refractory
disease or short-lived responses with standard therapies.
In this meta-analysis, allogeneic SCT was associated
with statistically superior clinical outcomes compared
to autologous SCT, which supports a potentially signif-
icant GVL effect in MF and SS. It is unclear whether do-
nor leukocyte infusions at the time of relapse or in the
case of persistent disease following transplant may also
have an impact on disease outcome. The encouraging
results from this study further validate the selection of al-
logeneic over autologous hematopoietic SCT in the
management of advanced MF or SS [4], and support
the need for further investigation of optimal strategies
for allogeneic hematopoietic HSCT in MF and SS.
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